Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.

Development of WRAIR’s Pan-Coronavirus Vaccine Shows Promise

Image of A vial of spike ferritin nanoparticle WRAIR's COVID-19 vaccine. A vial of spike ferritin nanoparticle (SpFN), WRAIR’s COVID-19 vaccine. Built on a ferritin platform, the vaccine offers a flexible approach to targeting multiple variants of the virus that causes COVID-19 and potentially other coronaviruses as well (Photo by: Mike Walters, Walter Reed Army Institute of Research).

A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.

Scientists in WRAIR's Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking "pan-SARS" strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.

"The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases," said Dr. Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the Army lead for SpFN. "Our strategy has been to develop a 'pan-coronavirus' vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species."

Pre-clinical studies published today in Science Translational Medicine indicate that the SpFN vaccine protects non-human primates from disease caused by the original strain of SARS-CoV-2 and induces highly-potent and broadly-neutralizing antibody responses against major SARS-CoV-2 variants of concern including the SARS-CoV-1 virus that emerged in 2002.

SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN's potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN's immune profile to that of other COVID-19 vaccines already authorized for emergency use.

"This vaccine stands out in the COVID-19 vaccine landscape," Modjarrad said. "The repetitive and ordered display of the coronavirus spike protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection."

WRAIR developed a secondary candidate vaccine, a SARS-CoV-2 Spike Receptor-Binding Domain Ferritin Nanoparticle (RFN) vaccine, which targets a smaller part of the coronavirus Spike protein than the SpFN vaccine. Results from a study, published recently in the Proceedings of the National Academy of Sciences, show that this vaccine potentially offers similar protection against an array of SARS-CoV-2 variants and SARS-CoV-1.

"The RFN vaccine candidate is more compact and has some natural advantages as we try to increase the immune response against multiple coronaviruses using a single vaccine platform, so it is still under consideration as part of our pan-coronavirus vaccine development pipeline," said Dr. Gordon Joyce, WRAIR structural biologist and vaccine co-inventor.

"The threat from COVID-19 continues as it evolves, and eventually there will be other emerging disease threats," said Dr. Nelson Michael, director of the Center for Infectious Diseases Research at WRAIR. "Our investment in developing a next generation vaccine is an important step towards getting ahead of COVID-19 and future disease threats."

You also may be interested in...

Technical Document
Jan 31, 2022

DOD COVID-19 Practice Management Guide Version 8

.PDF | 19.49 MB

This Practice Management Guide does not supersede DOD Policy. It is based upon the best information available at the time of publication. It is designed to provide information and assist decision making. It is not intended to define a standard of care and should not be construed as one. Neither should it be interpreted as prescribing an exclusive ...

Technical Document
Mar 4, 2021

DOD COVID-19 Practice Management Guide Version 7

.PDF | 11.73 MB

This Practice Management Guide does not supersede DOD Policy. It is based upon the best information available at the time of publication. It is designed to provide information and assist decision making. It is not intended to define a standard of care and should not be construed as one. Neither should it be interpreted as prescribing an exclusive ...

Technical Document
Mar 24, 2020

DOD COVID-19 Practice Management Guide

.PDF | 2.89 MB

This COVID-19 Practice Management Guide has been rapidly and thoughtfully developed by a multi-specialty group of 60 subject matter experts from across the Department of Defense Military Health System. This Practice Management Guideline consolidates resources and optimizes the management of patients requiring clinical care during the global COVID-19 ...

Refine your search
Last Updated: July 11, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery